Ionis Pharmaceuticals, Inc. (IONS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Carlsbad, CA, United States. The current CEO is Brett Monia.
IONS has IPO date of 1991-05-17, 1,069 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $12.68B.
Ionis Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, specializing in the discovery and development of RNA-targeted therapeutics. The company markets approved treatments including SPINRAZA for spinal muscular atrophy, TEGSEDI for hereditary transthyretin-mediated amyloidosis, and WAYLIVRA for familial lipid disorders, while maintaining a robust pipeline of Phase 3 candidates targeting rare genetic diseases, cardiovascular conditions, and neurological disorders. Through strategic collaborations with major pharmaceutical partners including Biogen, AstraZeneca, Bayer, GlaxoSmithKline, Novartis, and Roche, Ionis is advancing its platform across metabolic diseases, infectious diseases, renal diseases, and oncology.
